- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Topiramate effective as add-on therapy for weight loss in schizophrenia
South Asians are prone to more metabolic disorders and thus the effects of schizophrenia per se and its therapy on metabolic profile of an individual is significant for this population. Topiramate, which helps in weight reduction, can be useful add on drug in this regard as has been recently shown by Chandradasa et al in their recently published study in Asian Journal of Psychiatry.
A significant proportion of early deaths in SCZ are found to be due to cardiovascular diseases and related complications. Atypical antipsychotics are associated with more metabolic complications, including weight gain than the typical antipsychotics. Topiramate has been previously used to counter the weight gain induced by olanzapine. The present study was conducted to determine the effectiveness of topiramate in reducing the weight of overweight/obese persons with schizophrenia and to assess the potential change in psychiatric symptomatology as measured by the brief psychiatric rating scale (BPRS)
In this double-blind randomised control trial, 50 patients (each) were compared taking topiramate 100 mg/day with a placebo in overweight/obese adults with schizophrenia who have been on antipsychotics for at least a year. A monthly anthropometric measurements and assessed the symptomatology using the brief psychiatric rating scale (BPRS) was obtained.
It was found that out of total 100 patients, the one's with Topiramate add-on therapy led to significant weight/Body Mass Index reduction and improved symptomatology as measured by the BPRS compared to the placebo. The mean weight difference in 3 months was -3.02 kg for the topiramate group and 0.30 kg for the placebo group.
The topiramate group had significantly more reporting of loss of appetite. The number needed to treat (NNT) to have a 5% reduction of body weight was 4 with topiramate compared with the placebo.
This is the RCT with most participants assessing the use of topiramate in schizophrenia and only the second in South Asia. Topiramate was shown to be useful for weight reduction and symptomatic improvement in persons with schizophrenia.
Source: Asian Journal of Psychiatry: doi: 10.1016/j.ajp.2021.102963.
M.B.B.S, M.D. Psychiatry
M.B.B.S, M.D. Psychiatry (Teerthanker Mahavir University, U.P.) Currently working as Senior Resident in Department of Psychiatry, Institute of Human Behaviour and Allied Sciences (IHBAS) Dilshad Garden, New Delhi. Actively involved in various research activities of the department.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751